SEUD congress

Key Points

• Quality of life significantly improves for women using linzagolix, alleviating symptoms associated with uterine fibroids.
• Results indicate a reduction in symptom severity during treatment, making daily activities easier for affected women.
• Phase 3 trials assessed the impact of linzagolix on heavy menstrual bleeding, showing positive outcomes across participants.
• Findings highlight the potential benefits of linzagolix for women, supporting its use as an effective treatment option.

Abstract